Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Jefferies to hold a virtual conference » 04:55
11/18/21
11/18
04:55
11/18/21
04:55
ALXO

ALX Oncology

$42.93 /

-2.02 (-4.49%)

, GLTO

Galecto

$3.05 /

-0.13 (-4.09%)

, NBTX

Nanobiotix

$9.35 /

-0.2 (-2.09%)

, EXAS

Exact Sciences

$88.36 /

-3.12 (-3.41%)

, RXDX

Prometheus

$38.32 /

+2.32 (+6.44%)

, ARWR

Arrowhead

$63.75 /

-0.07 (-0.11%)

, PNT

Point Biopharma

$8.90 /

-0.13 (-1.44%)

, CNCE

Concert Pharmaceuticals

$3.99 /

-0.08 (-1.97%)

, AFMD

Affimed

$6.73 /

+0.605 (+9.88%)

, EPIX

Essa Pharma

$13.00 /

-0.31 (-2.33%)

, GRTX

Galera Therapeutics

$1.69 /

+0.015 (+0.90%)

, INAB

In8bio

$8.05 /

+ (+0.00%)

, KROS

Keros Therapeutics

$60.31 /

-2.51 (-4.00%)

, LABP

Landos Biopharma

$10.17 /

-0.55 (-5.13%)

, SVRA

Savara

$1.12 /

-0.005 (-0.45%)

, STRO

Sutro Biopharma

$18.47 /

-0.57 (-2.99%)

, VACC

Vaccitech

$12.70 /

+0.01 (+0.08%)

, ZNTL

Zentalis

$79.38 /

+2.39 (+3.10%)

London Healthcare Virtual…

London Healthcare Virtual Conference 2021 to be held on November 16-18.

ShowHide Related Items >><<
ZNTL Zentalis
$79.38 /

+2.39 (+3.10%)

VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

SVRA Savara
$1.12 /

-0.005 (-0.45%)

STRO Sutro Biopharma
$18.47 /

-0.57 (-2.99%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

PNT Point Biopharma
$8.90 /

-0.13 (-1.44%)

NBTX Nanobiotix
$9.35 /

-0.2 (-2.09%)

LABP Landos Biopharma
$10.17 /

-0.55 (-5.13%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

INAB In8bio
$8.05 /

+ (+0.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

GLTO Galecto
$3.05 /

-0.13 (-4.09%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

CNCE Concert Pharmaceuticals
$3.99 /

-0.08 (-1.97%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

ALXO ALX Oncology
$42.93 /

-2.02 (-4.49%)

AFMD Affimed
$6.73 /

+0.605 (+9.88%)

ALXO ALX Oncology
$42.93 /

-2.02 (-4.49%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
GLTO Galecto
$3.05 /

-0.13 (-4.09%)

04/26/21 Credit Suisse
Galecto assumed with an Outperform at Credit Suisse
03/16/21 Credit Suisse
Galecto price target lowered to $12 from $29 at Credit Suisse
11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
NBTX Nanobiotix
$9.35 /

-0.2 (-2.09%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

11/15/21 Oppenheimer
Prometheus downgraded to Perform from Outperform at Oppenheimer
11/12/21
Fly Intel: Top five analyst initiations
11/12/21 Stifel
Prometheus resumed with a Buy at Stifel
10/04/21 Oppenheimer
Prometheus initiated with an Outperform at Oppenheimer
ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
10/26/21 Piper Sandler
Key opinion leaders see Arrowhead's C3 as promising target, says Piper Sandler
PNT Point Biopharma
$8.90 /

-0.13 (-1.44%)

09/28/21 Piper Sandler
Point Biopharma exercises global license with Bach, says Piper Sandler
07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
CNCE Concert Pharmaceuticals
$3.99 /

-0.08 (-1.97%)

11/12/21 JMP Securities
Concert Pharmaceuticals price target lowered to $10 from $17 at JMP Securities
10/05/21 Mizuho
Concert Pharmaceuticals price target lowered to $9 from $13 at Mizuho
02/02/21 Truist
Concert Pharmaceuticals price target lowered to $22 from $30 at Truist
02/02/21 Mizuho
Concert shares oversold on schizophrenia failure, says Mizuho
AFMD Affimed
$6.73 /

+0.605 (+9.88%)

11/17/21 Berenberg
Affimed initiated with a Buy at Berenberg
10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
INAB In8bio
$8.05 /

+ (+0.00%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

08/06/21 Piper Sandler
Keros Therapeutics price target lowered to $90 from $95 at Piper Sandler
06/24/21 Piper Sandler
Keros MDS data establishes proof-of-concept, says Piper Sandler
12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
LABP Landos Biopharma
$10.17 /

-0.55 (-5.13%)

11/16/21 SVB Leerink
SVB Leerink downgrades Landos Biopharma to Market Perform, cuts target to $16
11/16/21 SVB Leerink
Landos Biopharma downgraded to Market Perform from Outperform at SVB Leerink
11/15/21 JonesTrading
JonesTrading downgrades Landos Biopharma after 'best reset' of strategy
11/15/21 JonesTrading
Landos Biopharma downgraded to Hold from Buy at JonesTrading
SVRA Savara
$1.12 /

-0.005 (-0.45%)

09/10/21 Piper Sandler
Piper 'even more bullish' on Savara study after management meeting
06/30/21 Piper Sandler
Savara doses first patient in IMPALA-2 study, says Piper Sandler
05/24/21 Oppenheimer
Oppenheimer says Savara should not be overlooked, ups target to $5
04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
STRO Sutro Biopharma
$18.47 /

-0.57 (-2.99%)

11/17/21 Berenberg
Sutro Biopharma initiated with a Buy at Berenberg
06/18/21
Fly Intel: Top five analyst initiations
06/18/21 H.C. Wainwright
Sutro Biopharma initiated with a Buy at H.C. Wainwright
05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$79.38 /

+2.39 (+3.10%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$79.38 /

+2.39 (+3.10%)

VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

SVRA Savara
$1.12 /

-0.005 (-0.45%)

STRO Sutro Biopharma
$18.47 /

-0.57 (-2.99%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

PNT Point Biopharma
$8.90 /

-0.13 (-1.44%)

NBTX Nanobiotix
$9.35 /

-0.2 (-2.09%)

LABP Landos Biopharma
$10.17 /

-0.55 (-5.13%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

GLTO Galecto
$3.05 /

-0.13 (-4.09%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

CNCE Concert Pharmaceuticals
$3.99 /

-0.08 (-1.97%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

AFMD Affimed
$6.73 /

+0.605 (+9.88%)

  • 30
    Jul
  • 29
    Jun
  • 30
    Apr
  • 11
    Mar
  • 12
    Mar
  • 18
    Feb
  • 04
    Feb
  • 13
    Jan
  • 13
    Jan
  • 10
    Dec
  • 09
    Dec
  • 11
    Dec
EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

VACC Vaccitech
$12.70 /

+0.01 (+0.08%)

SVRA Savara
$1.12 /

-0.005 (-0.45%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

INAB In8bio
$8.05 /

+ (+0.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

ARWR Arrowhead
$63.75 /

-0.07 (-0.11%)

ALXO ALX Oncology
$42.93 /

-2.02 (-4.49%)

AFMD Affimed
$6.73 /

+0.605 (+9.88%)

RXDX Prometheus
$38.32 /

+2.32 (+6.44%)

KROS Keros Therapeutics
$60.31 /

-2.51 (-4.00%)

GRTX Galera Therapeutics
$1.69 /

+0.015 (+0.90%)

GLTO Galecto
$3.05 /

-0.13 (-4.09%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
11/17/21
11/17
04:55
11/17/21
04:55
ALXO

ALX Oncology

$45.00 /

-1.185 (-2.57%)

, GLTO

Galecto

$3.18 /

-0.33 (-9.40%)

, NBTX

Nanobiotix

$9.50 /

+ (+0.00%)

, EXAS

Exact Sciences

$91.45 /

+1.56 (+1.74%)

, RXDX

Prometheus

$36.15 /

+1.75 (+5.09%)

, ARWR

Arrowhead

$63.96 /

-1.98 (-3.00%)

, PNT

Point Biopharma

$9.02 /

+0.17 (+1.92%)

, CNCE

Concert Pharmaceuticals

$4.07 /

+0.06 (+1.50%)

, AFMD

Affimed

$6.13 /

+0.095 (+1.57%)

, EPIX

Essa Pharma

$13.37 /

+0.4 (+3.08%)

, GRTX

Galera Therapeutics

$1.68 /

+0.005 (+0.30%)

, INAB

In8bio

$8.05 /

-0.13 (-1.59%)

, KROS

Keros Therapeutics

$62.90 /

+1.4 (+2.28%)

, LABP

Landos Biopharma

$10.65 /

-3.35 (-23.93%)

, SVRA

Savara

$1.12 /

-0.015 (-1.32%)

, STRO

Sutro Biopharma

$19.06 /

-0.04 (-0.21%)

, VACC

Vaccitech

$12.65 /

-0.17 (-1.33%)

, ZNTL

Zentalis

$76.99 /

-0.11 (-0.14%)

London Healthcare Virtual…

London Healthcare Virtual Conference 2021 to be held on November 16-18.

ShowHide Related Items >><<
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.06 /

-0.04 (-0.21%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

PNT Point Biopharma
$9.02 /

+0.17 (+1.92%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$10.65 /

-3.35 (-23.93%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

INAB In8bio
$8.05 /

-0.13 (-1.59%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

GLTO Galecto
$3.18 /

-0.33 (-9.40%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

AFMD Affimed
$6.13 /

+0.095 (+1.57%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
GLTO Galecto
$3.18 /

-0.33 (-9.40%)

04/26/21 Credit Suisse
Galecto assumed with an Outperform at Credit Suisse
03/16/21 Credit Suisse
Galecto price target lowered to $12 from $29 at Credit Suisse
11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
NBTX Nanobiotix
$9.50 /

+ (+0.00%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

11/15/21 Oppenheimer
Prometheus downgraded to Perform from Outperform at Oppenheimer
11/12/21
Fly Intel: Top five analyst initiations
11/12/21 Stifel
Prometheus resumed with a Buy at Stifel
10/04/21 Oppenheimer
Prometheus initiated with an Outperform at Oppenheimer
ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
10/26/21 Piper Sandler
Key opinion leaders see Arrowhead's C3 as promising target, says Piper Sandler
PNT Point Biopharma
$9.02 /

+0.17 (+1.92%)

09/28/21 Piper Sandler
Point Biopharma exercises global license with Bach, says Piper Sandler
07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

11/12/21 JMP Securities
Concert Pharmaceuticals price target lowered to $10 from $17 at JMP Securities
10/05/21 Mizuho
Concert Pharmaceuticals price target lowered to $9 from $13 at Mizuho
02/02/21 Truist
Concert Pharmaceuticals price target lowered to $22 from $30 at Truist
02/02/21 Mizuho
Concert shares oversold on schizophrenia failure, says Mizuho
AFMD Affimed
$6.13 /

+0.095 (+1.57%)

10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
09/29/21 Stifel
Affimed initiated with a Buy at Stifel
EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
INAB In8bio
$8.05 /

-0.13 (-1.59%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

08/06/21 Piper Sandler
Keros Therapeutics price target lowered to $90 from $95 at Piper Sandler
06/24/21 Piper Sandler
Keros MDS data establishes proof-of-concept, says Piper Sandler
12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
LABP Landos Biopharma
$10.65 /

-3.35 (-23.93%)

11/16/21 SVB Leerink
SVB Leerink downgrades Landos Biopharma to Market Perform, cuts target to $16
11/16/21 SVB Leerink
Landos Biopharma downgraded to Market Perform from Outperform at SVB Leerink
11/15/21 JonesTrading
JonesTrading downgrades Landos Biopharma after 'best reset' of strategy
11/15/21 JonesTrading
Landos Biopharma downgraded to Hold from Buy at JonesTrading
SVRA Savara
$1.12 /

-0.015 (-1.32%)

09/10/21 Piper Sandler
Piper 'even more bullish' on Savara study after management meeting
06/30/21 Piper Sandler
Savara doses first patient in IMPALA-2 study, says Piper Sandler
05/24/21 Oppenheimer
Oppenheimer says Savara should not be overlooked, ups target to $5
04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
STRO Sutro Biopharma
$19.06 /

-0.04 (-0.21%)

06/18/21
Fly Intel: Top five analyst initiations
06/18/21 H.C. Wainwright
Sutro Biopharma initiated with a Buy at H.C. Wainwright
05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$76.99 /

-0.11 (-0.14%)

VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.06 /

-0.04 (-0.21%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

PNT Point Biopharma
$9.02 /

+0.17 (+1.92%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$10.65 /

-3.35 (-23.93%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

GLTO Galecto
$3.18 /

-0.33 (-9.40%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

AFMD Affimed
$6.13 /

+0.095 (+1.57%)

  • 30
    Jul
  • 29
    Jun
  • 30
    Apr
  • 11
    Mar
  • 12
    Mar
  • 18
    Feb
  • 04
    Feb
  • 13
    Jan
  • 13
    Jan
  • 10
    Dec
  • 09
    Dec
  • 11
    Dec
EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

VACC Vaccitech
$12.65 /

-0.17 (-1.33%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

INAB In8bio
$8.05 /

-0.13 (-1.59%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

CNCE Concert Pharmaceuticals
$4.07 /

+0.06 (+1.50%)

ARWR Arrowhead
$63.96 /

-1.98 (-3.00%)

ALXO ALX Oncology
$45.00 /

-1.185 (-2.57%)

AFMD Affimed
$6.13 /

+0.095 (+1.57%)

RXDX Prometheus
$36.15 /

+1.75 (+5.09%)

KROS Keros Therapeutics
$62.90 /

+1.4 (+2.28%)

GRTX Galera Therapeutics
$1.68 /

+0.005 (+0.30%)

GLTO Galecto
$3.18 /

-0.33 (-9.40%)

EPIX Essa Pharma
$13.37 /

+0.4 (+3.08%)

Conference/Events
Jefferies to hold a virtual conference » 10:32
11/16/21
11/16
10:32
11/16/21
10:32
ALXO

ALX Oncology

$44.59 /

-1.59 (-3.44%)

, GLTO

Galecto

$3.48 /

-0.03 (-0.85%)

, NBTX

Nanobiotix

$9.50 /

+ (+0.00%)

, EXAS

Exact Sciences

$88.17 /

-1.72 (-1.91%)

, RXDX

Prometheus

$34.65 /

+0.25 (+0.73%)

, ARWR

Arrowhead

$64.90 /

-1.04 (-1.58%)

, PNT

Point Biopharma

$8.86 /

+0.01 (+0.11%)

, CNCE

Concert Pharmaceuticals

$3.95 /

-0.06 (-1.50%)

, AFMD

Affimed

$6.03 /

-0.005 (-0.08%)

, EPIX

Essa Pharma

$14.02 /

+1.05 (+8.10%)

, GRTX

Galera Therapeutics

$1.64 /

-0.03 (-1.80%)

, INAB

In8bio

$8.46 /

+0.28 (+3.42%)

, KROS

Keros Therapeutics

$62.28 /

+0.78 (+1.27%)

, LABP

Landos Biopharma

$12.89 /

-1.11 (-7.93%)

, SVRA

Savara

$1.12 /

-0.015 (-1.32%)

, STRO

Sutro Biopharma

$19.16 /

+0.06 (+0.31%)

, VACC

Vaccitech

$12.76 /

-0.06 (-0.47%)

, ZNTL

Zentalis

$77.86 /

+0.755 (+0.98%)

London Healthcare Virtual…

London Healthcare Virtual Conference 2021 to be held on November 16-18.

ShowHide Related Items >><<
ZNTL Zentalis
$77.86 /

+0.755 (+0.98%)

VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.16 /

+0.06 (+0.31%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

PNT Point Biopharma
$8.86 /

+0.01 (+0.11%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$12.89 /

-1.11 (-7.93%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

INAB In8bio
$8.46 /

+0.28 (+3.42%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

GLTO Galecto
$3.48 /

-0.03 (-0.85%)

EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

AFMD Affimed
$6.03 /

-0.005 (-0.08%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
GLTO Galecto
$3.48 /

-0.03 (-0.85%)

04/26/21 Credit Suisse
Galecto assumed with an Outperform at Credit Suisse
03/16/21 Credit Suisse
Galecto price target lowered to $12 from $29 at Credit Suisse
11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
NBTX Nanobiotix
$9.50 /

+ (+0.00%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

11/15/21 Oppenheimer
Prometheus downgraded to Perform from Outperform at Oppenheimer
11/12/21
Fly Intel: Top five analyst initiations
11/12/21 Stifel
Prometheus resumed with a Buy at Stifel
10/04/21 Oppenheimer
Prometheus initiated with an Outperform at Oppenheimer
ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
10/26/21 Piper Sandler
Key opinion leaders see Arrowhead's C3 as promising target, says Piper Sandler
PNT Point Biopharma
$8.86 /

+0.01 (+0.11%)

09/28/21 Piper Sandler
Point Biopharma exercises global license with Bach, says Piper Sandler
07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

11/12/21 JMP Securities
Concert Pharmaceuticals price target lowered to $10 from $17 at JMP Securities
10/05/21 Mizuho
Concert Pharmaceuticals price target lowered to $9 from $13 at Mizuho
02/02/21 Truist
Concert Pharmaceuticals price target lowered to $22 from $30 at Truist
02/02/21 Mizuho
Concert shares oversold on schizophrenia failure, says Mizuho
AFMD Affimed
$6.03 /

-0.005 (-0.08%)

10/21/21
Fly Intel: Top five analyst initiations
10/21/21 Truist
Affimed initiated with a Buy at Truist
10/21/21 Truist
Affimed initiated with a Buy at Truist
09/29/21 Stifel
Affimed initiated with a Buy at Stifel
EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
INAB In8bio
$8.46 /

+0.28 (+3.42%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

08/06/21 Piper Sandler
Keros Therapeutics price target lowered to $90 from $95 at Piper Sandler
06/24/21 Piper Sandler
Keros MDS data establishes proof-of-concept, says Piper Sandler
12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
LABP Landos Biopharma
$12.89 /

-1.11 (-7.93%)

11/16/21 SVB Leerink
SVB Leerink downgrades Landos Biopharma to Market Perform, cuts target to $16
11/16/21 SVB Leerink
Landos Biopharma downgraded to Market Perform from Outperform at SVB Leerink
11/15/21 JonesTrading
JonesTrading downgrades Landos Biopharma after 'best reset' of strategy
11/15/21 JonesTrading
Landos Biopharma downgraded to Hold from Buy at JonesTrading
SVRA Savara
$1.12 /

-0.015 (-1.32%)

09/10/21 Piper Sandler
Piper 'even more bullish' on Savara study after management meeting
06/30/21 Piper Sandler
Savara doses first patient in IMPALA-2 study, says Piper Sandler
05/24/21 Oppenheimer
Oppenheimer says Savara should not be overlooked, ups target to $5
04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
STRO Sutro Biopharma
$19.16 /

+0.06 (+0.31%)

06/18/21
Fly Intel: Top five analyst initiations
06/18/21 H.C. Wainwright
Sutro Biopharma initiated with a Buy at H.C. Wainwright
05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$77.86 /

+0.755 (+0.98%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Leerink
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$77.86 /

+0.755 (+0.98%)

VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

STRO Sutro Biopharma
$19.16 /

+0.06 (+0.31%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

PNT Point Biopharma
$8.86 /

+0.01 (+0.11%)

NBTX Nanobiotix
$9.50 /

+ (+0.00%)

LABP Landos Biopharma
$12.89 /

-1.11 (-7.93%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

GLTO Galecto
$3.48 /

-0.03 (-0.85%)

EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

AFMD Affimed
$6.03 /

-0.005 (-0.08%)

  • 30
    Jul
  • 29
    Jun
  • 30
    Apr
  • 11
    Mar
  • 12
    Mar
  • 18
    Feb
  • 04
    Feb
  • 13
    Jan
  • 13
    Jan
  • 10
    Dec
  • 09
    Dec
  • 11
    Dec
EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

VACC Vaccitech
$12.76 /

-0.06 (-0.47%)

SVRA Savara
$1.12 /

-0.015 (-1.32%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

INAB In8bio
$8.46 /

+0.28 (+3.42%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

EXAS Exact Sciences
$88.17 /

-1.72 (-1.91%)

EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

CNCE Concert Pharmaceuticals
$3.95 /

-0.06 (-1.50%)

ARWR Arrowhead
$64.90 /

-1.04 (-1.58%)

ALXO ALX Oncology
$44.59 /

-1.59 (-3.44%)

AFMD Affimed
$6.03 /

-0.005 (-0.08%)

RXDX Prometheus
$34.65 /

+0.25 (+0.73%)

KROS Keros Therapeutics
$62.28 /

+0.78 (+1.27%)

GRTX Galera Therapeutics
$1.64 /

-0.03 (-1.80%)

GLTO Galecto
$3.48 /

-0.03 (-0.85%)

EPIX Essa Pharma
$14.02 /

+1.05 (+8.10%)

Hot Stocks
Monopar Therapeutics plans to raise additional funds and/or engage partner » 08:11
11/12/21
11/12
08:11
11/12/21
08:11
MNPR

Monopar Therapeutics

$5.18 /

+0.38 (+7.92%)

Cash and cash equivalents…

Cash and cash equivalents as of September 30, 2021, were $22.3 million. Monopar anticipates that its current cash and cash equivalents will fund: the Phase 2b portion of the VOICE clinical trial; the commencement of the Phase 3 portion of the VOICE clinical trial; and the Phase 1b camsirubicin clinical trial through December 2022. The Company plans to raise additional funds and/or engage a partner within the next 12 months to complete the VOICE clinical program and continue camsirubicin clinical development beyond the Phase 1b clinical trial.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$5.18 /

+0.38 (+7.92%)

MNPR Monopar Therapeutics
$5.18 /

+0.38 (+7.92%)

11/01/21 H.C. Wainwright
Monopar Therapeutics initiated with a Buy at H.C. Wainwright
10/19/21 Roth Capital
Roth Capital bullish on Monopar Therapeutics after competitor trial fails
01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
MNPR Monopar Therapeutics
$5.18 /

+0.38 (+7.92%)

Earnings
Monopar Therapeutics reports Q3 EPS (20c), consensus (21c) » 08:10
11/12/21
11/12
08:10
11/12/21
08:10
MNPR

Monopar Therapeutics

$5.18 /

+0.38 (+7.92%)

R&D expenses for the…

R&D expenses for the third quarter of 2021 were $1.8 million compared to $1.2 million for the third quarter of 2020. This increase of $0.6 million was primarily due to increases of $0.5 million for VOICE clinical trial expenses and $0.2 million for R&D personnel expenses offset by a decrease of $0.1 million for Phase 1b camsirubicin clinical trial expenses.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$5.18 /

+0.38 (+7.92%)

MNPR Monopar Therapeutics
$5.18 /

+0.38 (+7.92%)

11/01/21 H.C. Wainwright
Monopar Therapeutics initiated with a Buy at H.C. Wainwright
10/19/21 Roth Capital
Roth Capital bullish on Monopar Therapeutics after competitor trial fails
01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
MNPR Monopar Therapeutics
$5.18 /

+0.38 (+7.92%)

Hot Stocks
Galera Therapeutics sees cash, cash equivalents funding operations into 2023 » 07:04
11/10/21
11/10
07:04
11/10/21
07:04
GRTX

Galera Therapeutics

$1.82 /

-0.055 (-2.93%)

As of September 30, 2021,…

As of September 30, 2021, Galera had cash, cash equivalents and short-term investments of $88.7M.

ShowHide Related Items >><<
GRTX Galera Therapeutics
$1.82 /

-0.055 (-2.93%)

GRTX Galera Therapeutics
$1.82 /

-0.055 (-2.93%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
GRTX Galera Therapeutics
$1.82 /

-0.055 (-2.93%)

GRTX Galera Therapeutics
$1.82 /

-0.055 (-2.93%)

GRTX Galera Therapeutics
$1.82 /

-0.055 (-2.93%)

Earnings
Galera Therapeutics reports Q3 EPS (86c), consensus (76c) » 07:03
11/10/21
11/10
07:03
11/10/21
07:03
GRTX

Galera Therapeutics

$1.82 /

-0.055 (-2.93%)

"We are…

"We are well-positioned financially to continue advancing our dismutase mimetic candidate rucosopasem in combination with stereotactic body radiation therapy in our randomized Phase 2 GRECO trials, with the goal of increasing the anti-cancer effectiveness of SBRT in patients with lung and pancreatic cancer," said Mel Sorensen, M.D., Galera's President and CEO. "We have already observed improved tumor outcomes and survival when combining one of our dismutase mimetics with SBRT in our randomized, placebo-controlled, proof-of-concept trial in patients with locally advanced pancreatic cancer, reported in September. We look forward to reporting initial data evaluating rucosopasem in lung cancer in the first half of next year." Dr. Sorensen continued: "Following the recent announcement of topline results of the Phase 3 ROMAN trial, we are continuing to analyze the data and evaluating next steps for avasopasem. While ROMAN did not achieve statistical significance in the primary endpoint of reducing SOM incidence, avasopasem was generally well tolerated and more than halved the number of days patients experienced this severe side effect resulting from radiation therapy."

ShowHide Related Items >><<
GRTX Galera Therapeutics
$1.82 /

-0.055 (-2.93%)

GRTX Galera Therapeutics
$1.82 /

-0.055 (-2.93%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
GRTX Galera Therapeutics
$1.82 /

-0.055 (-2.93%)

GRTX Galera Therapeutics
$1.82 /

-0.055 (-2.93%)

GRTX Galera Therapeutics
$1.82 /

-0.055 (-2.93%)

Over a month ago
Initiation
Monopar Therapeutics initiated with a Buy at H.C. Wainwright » 06:08
11/01/21
11/01
06:08
11/01/21
06:08
MNPR

Monopar Therapeutics

$4.81 /

-0.035 (-0.72%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Sean Lee initiated coverage of Monopar Therapeutics with a Buy rating and $9 price target. Monopar is a clinical-stage biotech company developing novel cancer therapies, Lee tells investors in a research note. The Validive Phase 2b/3 study is expected to report interim results in the first half of 2022 and could be a "major catalyst for the stock," says the analyst. He projects Validive to reach the market in 2025 and achieve risk-adjusted revenues of $111M by 2033.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$4.81 /

-0.035 (-0.72%)

MNPR Monopar Therapeutics
$4.81 /

-0.035 (-0.72%)

10/19/21 Roth Capital
Roth Capital bullish on Monopar Therapeutics after competitor trial fails
01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
MNPR Monopar Therapeutics
$4.81 /

-0.035 (-0.72%)

Hot Stocks
Monopar announces first patient dosed in Phase 1b trial on camsirubicin » 08:15
10/27/21
10/27
08:15
10/27/21
08:15
MNPR

Monopar Therapeutics

$4.62 /

-0.015 (-0.32%)

Monopar Therapeutics…

Monopar Therapeutics announced that the first patient has been dosed in its open-label dose-escalation Phase 1b clinical trial evaluating camsirubicin for the treatment of advanced soft tissue sarcoma, ASTS. "We are very pleased to have dosed our first patient so quickly after trial initiation and so soon following our FDA allowance to proceed in early August. The strong interest and support we are seeing within the oncology community for this study adds to our hopeful excitement and anticipation of the potential impact that escalating doses of camsirubicin may have on improving patient outcomes," said Chandler Robinson, MD, Monopar's Chief Executive Officer. An estimated 21 patients will be enrolled in the Phase 1b clinical trial, which is active and recruiting in the US.

ShowHide Related Items >><<
MNPR Monopar Therapeutics
$4.62 /

-0.015 (-0.32%)

MNPR Monopar Therapeutics
$4.62 /

-0.015 (-0.32%)

10/19/21 Roth Capital
Roth Capital bullish on Monopar Therapeutics after competitor trial fails
01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
MNPR Monopar Therapeutics
$4.62 /

-0.015 (-0.32%)

Conference/Events
American Society for Radiation Oncology to hold annual meeting » 04:55
10/27/21
10/27
04:55
10/27/21
04:55
ARAY

Accuray

$4.31 /

-0.08 (-1.82%)

, NVS

Novartis

$84.84 /

+1.49 (+1.79%)

, AZN

AstraZeneca

$62.29 /

+0.54 (+0.87%)

, BAYRY

Bayer

$14.20 /

+0.04 (+0.28%)

, BD

Budget Group

/

+

, BIOC

Biocept

$3.76 /

-0.08 (-2.08%)

, BSX

Boston Scientific

$44.32 /

-0.17 (-0.38%)

, BMY

Bristol-Myers

$58.24 /

+0.47 (+0.81%)

, EKTAY

Elekta

$11.58 /

+0.09 (+0.78%)

, GRTX

Galera Therapeutics

$1.88 /

+0.04 (+2.17%)

, DNA

Ginkgo Bioworks

$14.46 /

+0.19 (+1.33%)

, HTHIY

Hitachi

$118.77 /

-0.71 (-0.59%)

, MRK

Merck

$82.23 /

+0.545 (+0.67%)

, MYGN

Myriad Genetics

$30.66 /

-1.81 (-5.57%)

, NBTX

Nanobiotix

$12.35 /

-0.3 (-2.37%)

, NNOX

Nano-X Imaging

$22.54 /

-0.55 (-2.38%)

, NTRA

Natera

$115.95 /

+0.2 (+0.17%)

, NVCR

Novocure

$113.51 /

-5.91 (-4.95%)

, PHG

Philips

$47.69 /

-0.12 (-0.25%)

, REGN

Regeneron

$592.37 /

+16.45 (+2.86%)

, SNY

Sanofi

$49.98 /

+0.125 (+0.25%)

, SGEN

Seagen

$177.70 /

+2.29 (+1.31%)

, SMMNY

Siemens Healthineers

$34.66 /

-0.07 (-0.20%)

, SYK

Stryker

$273.25 /

+0.08 (+0.03%)

, TDY

Teledyne

$437.11 /

-7.89 (-1.77%)

, VRAY

ViewRay

$6.96 /

-0.05 (-0.71%)

, VREX

Varex Imaging

$26.36 /

-0.7 (-2.59%)

63rd Annual ASTRO Meeting…

63rd Annual ASTRO Meeting 2021 will be held in Chicago on October 24-27.Webcast Link

ShowHide Related Items >><<
VRAY ViewRay
$6.96 /

-0.05 (-0.71%)

TDY Teledyne
$437.11 /

-7.89 (-1.77%)

SYK Stryker
$273.25 /

+0.08 (+0.03%)

SNY Sanofi
$49.98 /

+0.125 (+0.25%)

SMMNY Siemens Healthineers
$34.66 /

-0.07 (-0.20%)

SGEN Seagen
$177.70 /

+2.29 (+1.31%)

REGN Regeneron
$592.37 /

+16.45 (+2.86%)

PHG Philips
$47.69 /

-0.12 (-0.25%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

NVCR Novocure
$113.51 /

-5.91 (-4.95%)

NTRA Natera
$115.95 /

+0.2 (+0.17%)

NNOX Nano-X Imaging
$22.54 /

-0.55 (-2.38%)

NBTX Nanobiotix
$12.35 /

-0.3 (-2.37%)

MYGN Myriad Genetics
$30.66 /

-1.81 (-5.57%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

HTHIY Hitachi
$118.77 /

-0.71 (-0.59%)

GRTX Galera Therapeutics
$1.88 /

+0.04 (+2.17%)

EKTAY Elekta
$11.58 /

+0.09 (+0.78%)

DNA Ginkgo Bioworks
$14.46 /

+0.19 (+1.33%)

BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BIOC Biocept
$3.76 /

-0.08 (-2.08%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

ARAY Accuray
$4.31 /

-0.08 (-1.82%)

ARAY Accuray
$4.31 /

-0.08 (-1.82%)

10/26/21 Lake Street
Investors should buy Accuray after 'excellent' ASTRO meeting, says Lake Street
01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Northland
Accuray initiated with an Outperform at Northland
NVS Novartis
$84.84 /

+1.49 (+1.79%)

10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
10/08/21 UBS
Novartis price target lowered to CHF 92 from CHF 95 at UBS
09/29/21 Stifel
Blueprint Medicines rersumed with a Hold at Stifel
09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
10/11/21 Deutsche Bank
AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
09/29/21 H.C. Wainwright
H.C. Wainwright says Astra deal for Caelum to yield 'nice check' for Fortress
BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

10/21/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
BD Budget Group
/

+

BIOC Biocept
$3.76 /

-0.08 (-2.08%)

10/08/21 Brookline
Biocept assumed with a Buy at Brookline
BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

10/06/21 Piper Sandler
Boston Scientific acquisition of Baylis looks 'solid,' says Piper Sandler
09/22/21 Piper Sandler
Boston Scientific said unlikely to hit low end of Q3 sales outlook, notes Piper
09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
08/31/21 BTIG
Abbott price target raised to $136 from $126 at BTIG
BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
10/25/21 SVB Leerink
Potential Bristol takeover of Aurinia makes strategic sense, says SVB Leerink
10/25/21 Citi
Bristol-Myers report of Aurinia approach 'looks credible,' says Citi
10/12/21 Morgan Stanley
Bristol-Myers price target lowered to $66 from $71 at Morgan Stanley
EKTAY Elekta
$11.58 /

+0.09 (+0.78%)

08/27/21 JPMorgan
Elekta price target raised to SEK 95 from SEK 91 at JPMorgan
06/02/21 JPMorgan
Elekta price target raised to SEK 91 from SEK 82 at JPMorgan
04/27/21 JPMorgan
Elekta price target raised to SEK 82 from SEK 80 at JPMorgan
03/18/21 JPMorgan
Elekta downgraded to Underweight from Neutral at JPMorgan
GRTX Galera Therapeutics
$1.88 /

+0.04 (+2.17%)

10/21/21 Citi
Galera Therapeutics price target lowered to $11 from $21 at Citi
10/20/21 H.C. Wainwright
Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
10/19/21 BofA
Galera double downgraded to Underperform at BofA after ROMAN trial miss
10/19/21 BofA
Galera Therapeutics downgraded to Underperform from Buy at BofA
DNA Ginkgo Bioworks
$14.46 /

+0.19 (+1.33%)

10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
10/13/21 Raymond James
Ginkgo Bioworks initiated with an Outperform at Raymond James
10/12/21 William Blair
Blair starts Ginkgo at Outperform on 'significant' competitive advantage
10/12/21 William Blair
Ginkgo Bioworks initiated with an Outperform at William Blair
HTHIY Hitachi
$118.77 /

-0.71 (-0.59%)

11/20/20 Goldman Sachs
Hitachi reinstated with a Sell at Goldman Sachs
MRK Merck
$82.23 /

+0.545 (+0.67%)

10/22/21 SVB Leerink
Merck price target raised to $105 from $104 at SVB Leerink
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/19/21 Evercore ISI
Atea's Phase 2 design disappoints, but drug has not failed, says Evercore ISI
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
MYGN Myriad Genetics
$30.66 /

-1.81 (-5.57%)

10/14/21 Cowen
Myriad Genetics coverage transferred at Cowen
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Myriad Genetics initiated with a Market Perform at Raymond James
06/03/21 Goldman Sachs
Myriad Genetics initiated with a Sell at Goldman Sachs
NBTX Nanobiotix
$12.35 /

-0.3 (-2.37%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
NNOX Nano-X Imaging
$22.54 /

-0.55 (-2.38%)

04/19/21 Ladenburg
Ladenburg starts Nano-X Imaging at Buy with $52 price target
04/19/21 Ladenburg
Nano-X Imaging initiated with a Buy at Ladenburg
02/01/21 Cantor Fitzgerald
Cantor Fitzgerald reiterates Overweight on Nano-X Imaging, lowers target to $67
NTRA Natera
$115.95 /

+0.2 (+0.17%)

10/19/21 Canaccord
Natera Prospera Lung launch to continue momentum, says Canaccord
10/14/21 Cowen
Natera coverage transferred at Cowen
08/31/21 Craig-Hallum
Natera seeks to challenge CareDx franchise with launch, says Craig-Hallum
08/09/21 Piper Sandler
Natera price target raised to $160 from $155 at Piper Sandler
NVCR Novocure
$113.51 /

-5.91 (-4.95%)

10/25/21 Piper Sandler
Novocure price target lowered to $195 from $235 at Piper Sandler
09/21/21 Piper Sandler
Novocure clinical update should come in next few weeks, says Piper Sandler
07/30/21 Mizuho
Novocure price target lowered to $200 from $229 at Mizuho
PHG Philips
$47.69 /

-0.12 (-0.25%)

10/25/21 Credit Suisse
Philips price target lowered to EUR 42 from EUR 49 at Credit Suisse
10/19/21 JPMorgan
Philips price target lowered to EUR 36.40 from EUR 40.90 at JPMorgan
10/19/21 Deutsche Bank
Philips price target lowered to EUR 42 from EUR 43 at Deutsche Bank
09/10/21 Barclays
Philips price target lowered to EUR 53 from EUR 54 at Barclays
REGN Regeneron
$592.37 /

+16.45 (+2.86%)

10/26/21 SVB Leerink
Regeneron price target raised to $798 from $785 at SVB Leerink
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/22/21 H.C. Wainwright
Regeneron price target raised to $842 from $831 at H.C. Wainwright
10/14/21 H.C. Wainwright
H.C. Wainwright 'enthusiastic' on Regeneron, sees no barrier for REGEN-COV nod
SNY Sanofi
$49.98 /

+0.125 (+0.25%)

10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
09/27/21 SVB Leerink
Sanofi upgraded to Outperform from Market Perform at SVB Leerink
SGEN Seagen
$177.70 /

+2.29 (+1.31%)

10/14/21 BTIG
Seagen assumed with a Neutral at BTIG
09/27/21 RBC Capital
Seagen price target raised to $154 from $148 at RBC Capital
05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
SMMNY Siemens Healthineers
$34.66 /

-0.07 (-0.20%)

10/13/21 UBS
Siemens Healthineers price target raised to EUR 54 from EUR 48 at UBS
10/01/21 Societe Generale
Siemens Healthineers downgraded to Hold at Societe Generale
10/01/21 Societe Generale
Siemens Healthineers downgraded to Hold from Buy at Societe Generale
09/10/21 Barclays
Siemens Healthineers price target raised to EUR 55 from EUR 49 at Barclays
SYK Stryker
$273.25 /

+0.08 (+0.03%)

09/14/21 Raymond James
Stryker resumed with a Market Perform at Raymond James
07/29/21 Argus
Stryker price target raised to $320 from $280 at Argus
07/28/21
Fly Intel: Top five analyst upgrades
07/28/21 SVB Leerink
Stryker price target raised to $300 from $290 at SVB Leerink
TDY Teledyne
$437.11 /

-7.89 (-1.77%)

07/30/21 Cowen
Teledyne price target raised to $525 from $500 at Cowen
06/08/21 Goldman Sachs
Teledyne reinstated with a Neutral at Goldman Sachs
05/25/21 BofA
Teledyne initiated with a Buy at BofA
04/29/21 Needham
Teledyne price target raised to $500 from $416 at Needham
VRAY ViewRay
$6.96 /

-0.05 (-0.71%)

10/19/21 Piper Sandler
ViewRay strength attributed to MIRAGE study recruiting halt, says Piper Sandler
10/14/21 B. Riley
ViewRay resumed with a Neutral at B. Riley
10/14/21 B. Riley
ViewRay resumed with a Neutral at B. Riley
06/25/21 Morgan Stanley
ViewRay upgraded to Equal Weight from Underweight at Morgan Stanley
VREX Varex Imaging
$26.36 /

-0.7 (-2.59%)

02/05/21 Oppenheimer
Varex Imaging upgraded to Outperform from Perform at Oppenheimer
VREX Varex Imaging
$26.36 /

-0.7 (-2.59%)

VRAY ViewRay
$6.96 /

-0.05 (-0.71%)

TDY Teledyne
$437.11 /

-7.89 (-1.77%)

SYK Stryker
$273.25 /

+0.08 (+0.03%)

SNY Sanofi
$49.98 /

+0.125 (+0.25%)

SGEN Seagen
$177.70 /

+2.29 (+1.31%)

REGN Regeneron
$592.37 /

+16.45 (+2.86%)

PHG Philips
$47.69 /

-0.12 (-0.25%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

NVCR Novocure
$113.51 /

-5.91 (-4.95%)

NTRA Natera
$115.95 /

+0.2 (+0.17%)

NNOX Nano-X Imaging
$22.54 /

-0.55 (-2.38%)

NBTX Nanobiotix
$12.35 /

-0.3 (-2.37%)

MYGN Myriad Genetics
$30.66 /

-1.81 (-5.57%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

GRTX Galera Therapeutics
$1.88 /

+0.04 (+2.17%)

BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BIOC Biocept
$3.76 /

-0.08 (-2.08%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

ARAY Accuray
$4.31 /

-0.08 (-1.82%)

  • 22
    Jul
  • 11
    Feb
  • 22
    Jan
  • 05
    Jan
  • 11
    Dec
SNY Sanofi
$49.98 /

+0.125 (+0.25%)

REGN Regeneron
$592.37 /

+16.45 (+2.86%)

PHG Philips
$47.69 /

-0.12 (-0.25%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

HTHIY Hitachi
$118.77 /

-0.71 (-0.59%)

DNA Ginkgo Bioworks
$14.46 /

+0.19 (+1.33%)

BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

VREX Varex Imaging
$26.36 /

-0.7 (-2.59%)

SYK Stryker
$273.25 /

+0.08 (+0.03%)

SNY Sanofi
$49.98 /

+0.125 (+0.25%)

SMMNY Siemens Healthineers
$34.66 /

-0.07 (-0.20%)

SGEN Seagen
$177.70 /

+2.29 (+1.31%)

REGN Regeneron
$592.37 /

+16.45 (+2.86%)

PHG Philips
$47.69 /

-0.12 (-0.25%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

NVCR Novocure
$113.51 /

-5.91 (-4.95%)

NTRA Natera
$115.95 /

+0.2 (+0.17%)

NNOX Nano-X Imaging
$22.54 /

-0.55 (-2.38%)

MYGN Myriad Genetics
$30.66 /

-1.81 (-5.57%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

GRTX Galera Therapeutics
$1.88 /

+0.04 (+2.17%)

DNA Ginkgo Bioworks
$14.46 /

+0.19 (+1.33%)

BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

TDY Teledyne
$437.11 /

-7.89 (-1.77%)

REGN Regeneron
$592.37 /

+16.45 (+2.86%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

NNOX Nano-X Imaging
$22.54 /

-0.55 (-2.38%)

MRK Merck
$82.23 /

+0.545 (+0.67%)

GRTX Galera Therapeutics
$1.88 /

+0.04 (+2.17%)

DNA Ginkgo Bioworks
$14.46 /

+0.19 (+1.33%)

BSX Boston Scientific
$44.32 /

-0.17 (-0.38%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.